These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 23963633

  • 1. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
    Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T.
    Calcif Tissue Int; 2014 Feb; 94(2):170-5. PubMed ID: 23963633
    [Abstract] [Full Text] [Related]

  • 2. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 3. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
    Tanaka S, Kuroda T, Sugimoto T, Nakamura T, Shiraki M.
    Curr Med Res Opin; 2014 May; 30(5):931-6. PubMed ID: 24392946
    [Abstract] [Full Text] [Related]

  • 4. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 5. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
    Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T.
    Osteoporos Int; 2019 Nov 16; 30(11):2321-2331. PubMed ID: 31392401
    [Abstract] [Full Text] [Related]

  • 6. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.
    Curr Med Res Opin; 2013 Mar 16; 29(3):195-203. PubMed ID: 23259702
    [Abstract] [Full Text] [Related]

  • 7. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
    Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV.
    Osteoporos Int; 2015 Nov 16; 26(11):2677-84. PubMed ID: 26092063
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
    Harvey NC, Kanis JA, Odén A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H, McCloskey EV.
    Osteoporos Int; 2015 Sep 16; 26(9):2347-53. PubMed ID: 26092062
    [Abstract] [Full Text] [Related]

  • 9. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
    Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S.
    Osteoporos Int; 2021 Nov 16; 32(11):2301-2311. PubMed ID: 34002252
    [Abstract] [Full Text] [Related]

  • 10. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
    Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH.
    Osteoporos Int; 2005 May 16; 16(5):510-6. PubMed ID: 15322742
    [Abstract] [Full Text] [Related]

  • 11. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
    Shiraki M, Ueda S, Sugimoto T, Kuroda T, Nakamura T.
    Osteoporos Int; 2016 Oct 16; 27(10):3057-62. PubMed ID: 27234671
    [Abstract] [Full Text] [Related]

  • 12. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov 16; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 13. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H, Narita R, Yokoyama Y, Watanabe M, Tomomitsu M.
    Osteoporos Int; 2019 Oct 16; 30(10):2027-2037. PubMed ID: 31243480
    [Abstract] [Full Text] [Related]

  • 14. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
    Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S.
    Osteoporos Int; 2023 Jan 16; 34(1):189-199. PubMed ID: 36239756
    [Abstract] [Full Text] [Related]

  • 15. A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.
    Chen JF, Yang KH, Zhang ZL, Chang HC, Chen Y, Sowa H, Gürbüz S.
    Osteoporos Int; 2015 Jan 16; 26(1):11-28. PubMed ID: 25138261
    [Abstract] [Full Text] [Related]

  • 16. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Takaichi K.
    Osteoporos Int; 2016 Apr 16; 27(4):1441-1450. PubMed ID: 26525045
    [Abstract] [Full Text] [Related]

  • 17. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.
    J Bone Miner Metab; 2014 Jul 16; 32(4):441-6. PubMed ID: 24213216
    [Abstract] [Full Text] [Related]

  • 18. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A.
    Clin Calcium; 2012 Mar 16; 22(3):387-98. PubMed ID: 22370306
    [Abstract] [Full Text] [Related]

  • 19. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
    Lancet; 2018 Jan 20; 391(10117):230-240. PubMed ID: 29129436
    [Abstract] [Full Text] [Related]

  • 20. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
    Oswald AJ, Berg J, Milne G, Ralston SH.
    Calcif Tissue Int; 2014 Feb 20; 94(2):176-82. PubMed ID: 24026567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.